Drug Profile

Guanfacine extended release - Neuraxpharm

Latest Information Update: 08 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neuraxpharm
Class Acetamides; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
Mechanism of Action Alpha 2 adrenergic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Jan 2024 Preclinical trials in Unspecified in Germany (PO) before January 2024
31 Jan 2024 Neuraxpharm plans a phase I bioequivalence trial in healthy volunteers in Romania (PO, Tablet) (GFC-BEMD-01-NXP/23) (EudraCT 2023-506596-10-00) (CTIS2023-506596-10-00)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com